WHO downgrades status of oseltamivir

@article{Ebell2017WHODS,
  title={WHO downgrades status of oseltamivir},
  author={Mark H. Ebell},
  journal={British Medical Journal},
  year={2017},
  volume={358}
}
  • M. Ebell
  • Published 12 July 2017
  • Geology
  • British Medical Journal
Important lessons from the Tamiflu story 

Molnupiravir’s authorisation was premature

Regulatory decisions fall short of the wise stewardship required during a pandemic

Covid-19: What now for remdesivir?

The spectre of past pandemics looms large over remdesivir, one of the first drug treatments for covid-19. With a WHO trial finding little benefit, Jeremy Hsu asks if the expensive drug is just

The REMAP-CAP (Randomized Embedded Multifactorial Adaptive Platform for Community-acquired Pneumonia) Study. Rationale and Design

A large, international trial that combines features of adaptive platform trials with pragmatic point-of-care trials to determine best treatment strategies for patients admitted to an intensive care unit with severe community-acquired pneumonia is presented.

Repurposing drugs targeting the P2X7 receptor to limit hyperinflammation and disease during influenza virus infection

It is demonstrated that the NLRP3 inflammasome plays time‐dependent roles during severe IAV infection with early protective responses and later dysregulation leading to excessive inflammation, contributing to disease severity.

Antivirals for influenza-Like Illness? A randomised Controlled trial of Clinical and Cost effectiveness in primary CarE (ALIC4 E): the ALIC4 E protocol

The primary objective is to determine whether adding antiviral treatment to best usual primary care is effective in reducing time to return to usual daily activity with fever, headache and muscle ache reduced to minor severity or less.